Acorda to Present New Research on AMPYRA® at Fifth Cooperative Meeting of CMSC and ACTRIMS

ARDSLEY, N.Y.--(BUSINESS WIRE)--

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present new research data on AMPYRA (dalfampridine) Extended Release Tablets, 10 mg at the 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), being held in Orlando, FL, May 29 June 1. AMPYRA is an FDA-approved therapy indicated to improve walking in people with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.

The results of the STEADY study being presented at CMSC expand our understanding of how AMPYRA may improve various dimensions of walking in people with MS and guide us towards endpoints for future studies, said Adrian Rabinowicz, M.D., FAAN, Acordas Senior Vice President of Clinical Development and Medical Affairs. We are sponsoring a range of studies aimed at exploring the use of AMPYRA within MS even as we look to potentially expand its use into post-stroke deficits and continue to develop other drugs in our pipeline such as rHIgM22 in MS, GGF2 in heart failure, and Diazepam Nasal Spray for treatment of certain epileptic seizures.

Data being presented on AMPYRA at the CMSC annual meeting include:

More detailed information on scientific sessions and data presentations at the CMSC annual meeting can be found on the conference website (http://annualmeeting.mscare.org/).

Important New Safety Information

Do not take AMPYRA if you are allergic to dalfampridine (4-aminopyridine), the active ingredient in AMPYRA.

Important Safety Information

Do not take AMPYRA if you have ever had a seizure, or have certain types of kidney problems, or are allergic to dalfampridine (4-aminopyridine), the active ingredient in AMPYRA.

Take AMPYRA exactly as prescribed by your doctor.

Go here to see the original:
Acorda to Present New Research on AMPYRA® at Fifth Cooperative Meeting of CMSC and ACTRIMS